Edition:
United Kingdom

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

520.15INR
10:28am BST
Change (% chg)

Rs1.30 (+0.25%)
Prev Close
Rs518.85
Open
Rs520.85
Day's High
Rs523.95
Day's Low
Rs516.10
Volume
863,057
Avg. Vol
1,663,546
52-wk High
Rs718.00
52-wk Low
Rs508.75

Latest Key Developments (Source: Significant Developments)

India's Biocon March-Qtr Consol Profit Surges
Thursday, 25 Apr 2019 

April 25 (Reuters) - Biocon Ltd ::MARCH QUARTER CONSOL PROFIT 2.14 BILLION RUPEES VERSUS PROFIT OF 1.30 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR MARCH QUARTER CONSOL PROFIT WAS 2.01 BILLION RUPEES.MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 15.29 BILLION RUPEES VERSUS 11.70 BILLION RUPEES LAST YEAR.SAYS - RECOMMENDED THE ISSUE OF BONUS SHARES BY CAPITALISATION OF FREE RESERVES IN THE RATIO OF 1:1.SEEKS SHAREHOLDERS' NOD FOR RE-APPOINTMENT OF ARUN SURESH CHANDAVARKAR AS CEO & JOINT MANAGING DIRECTOR.  Full Article

Biocon Says Biocon Facilities Complete Pre Approval U.S.FDA Inspection
Monday, 18 Feb 2019 

Feb 18 (Reuters) - Biocon Ltd ::SAYS BIOCON FACILITIES COMPLETE PRE APPROVAL U.S.FDA INSPECTION.BIOCON - THERE WERE NO OBSERVATIONS OND NO FORM 48J WAS ISSUED AFTER THE PRE-APPROVAL INSPECTION OF ORAL SOLID DOSAGE FACILITY.  Full Article

India's Biocon Dec-Qtr Profit Rises
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - Biocon Ltd ::DEC QUARTER CONSOL PROFIT 2.17 BILLION RUPEES VERSUS PROFIT OF 919 MILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR DEC QUARTER CONSOL PROFIT WAS 1.76 BILLION RUPEES.DEC QUARTER CONSOL REVENUE FROM OPERATIONS 15.41 BILLION RUPEES VERSUS 10.58 BILLION RUPEES LAST YEAR.  Full Article

Biocon Says FDA Issues Zero 483 Observations For Bengaluru Facility
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Biocon Ltd ::BIOCON - U.S. FDA CONDUCTED PRE APPROVAL INSPECTION OF ORAL SOLID DOSAGE FORMS MANUFACTURING FACILITY AT BIOCON PARK/ BENGALURU FROM NOV 05- NOV 09.BIOCON - AUDIT CONCLUDED WITHOUT ANY OBSERVATIONS AND NO FORM 483 WAS ISSUED.  Full Article

Biocon Says European Medicines Agency's CMPH Recommends Approval Of Fulphila
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Biocon Ltd ::BIOCON SAYS EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE HAS ISSUED POSITIVE OPINION RECOMMENDING APPROVAL OF FULPHILA.SAYS CHMP POSITIVE OPINION WILL NOW BE CONSIDERED BY THE EUROPEAN COMMISSION.SAYS DECISION ON APPROVAL IS EXPECTED BY NOVEMBER 2018.  Full Article

Biocon Q4 Net Profit Up 2 Percent
Thursday, 26 Apr 2018 

April 26 (Reuters) - Biocon Ltd ::Q4 NET PROFIT UP 2 PERCENT TO 1.30 BILLION RUPEES; Q4 TOTAL REVENUE 12.37 BILLION RUPEES VERSUS 9.74 BILLION RUPEES YEAR-AGO.  Full Article

Mylan, Biocon Seek To Accelerate Introduction Of Adalimumab Biosimilar In EU
Wednesday, 11 Apr 2018 

April 11 (Reuters) - Biocon Ltd ::MYLAN, BIOCON SEEK TO ACCELERATE INTRODUCTION OF ADALIMUMAB BIOSIMILAR IN EU.  Full Article

India's Biocon ‍Says U.S. FDA Completed Pre-Approval Inspection At Malaysia Unit ​
Wednesday, 21 Feb 2018 

Feb 21 (Reuters) - Biocon Ltd ::‍U.S. FDA COMPLETED PRE-APPROVAL INSPECTION AT MALAYSIA FACILITY AND ISSUED FORM 483 WITH 6 OBSERVATIONS​.  Full Article

Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Cytosorbents ::CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA.CYTOSORBENTS CORP - ‍BIOCON HAS EXCLUSIVE RIGHTS TO DISTRIBUTE CYTOSORB IN MALAYSIA, WHERE CYTOSORB IS ALREADY REGISTERED​.CYTOSORBENTS CORP - ‍FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED​.  Full Article

Mylan And Biocon Receive Positive CHMP Opinion For Semglee, Biosimilar Insulin Glargine
Monday, 29 Jan 2018 

Jan 29 (Reuters) - Biocon Ltd ::MYLAN AND BIOCON RECEIVE POSITIVE CHMP OPINION FOR SEMGLEE™, BIOSIMILAR INSULIN GLARGINE.MYLAN NV - CHMP POSITIVE OPINION WILL BE CONSIDERED BY EUROPEAN COMMISSION.MYLAN NV - EUROPEAN COMMISSION DECISION ON APPROVAL IS EXPECTED IN APRIL.MYLAN NV - EUROPEAN COMMISSION DECISION ON APPROVAL IS EXPECTED IN APRIL.MYLAN - IN ADDITION TO EUROPEAN SUBMISSION, MARKETING APPLICATIONS FOR SEMGLEE BEEN SUBMITTED IN AUSTRALIA, CANADA, U.S. & PLANNED FOR KEY EMERGING MARKETS.  Full Article

India's Biocon quarterly profit more than doubles, beats estimate

Jan 24 Indian biotechnology firm Biocon Ltd's quarterly profit more than doubled, handily beating analysts' estimates, largely driven by strong performance of its biologics businesses.

No consensus analysis data available.